HOME >> BIOLOGY >> NEWS
New cellular flaw found in some virulent breast cancers

Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment.

In the January issue of Cancer Cell, a team led by Qunyan Yu, MD, and Peter Sicinski, MD, PhD, of Dana-Farber report that the interaction of a certain mutated oncogene and the newly described growth control flaw is seen in about 10 percent of breast cancers and the deadliest ones.

The cancer results from a cascade of molecular events. The overproduction of a common protein, cyclin D1, hyperstimulates a growth switch, CDK4 kinase, causing it to unleash a virulent proliferation of cancer cells and creating a tumor with a very poor prognosis.

"The development of cancer drugs like Gleevec and Iressa have shown that it is possible to block the action of kinases," said Sicinski, "so we hope that these findings will stimulate interest in developing drugs to block CDK4 as a targeted approach to treating this very aggressive cancer."

Breast cancers composed of cells that contain both the overactive cyclin D1- CDK4 switch and a mutated cancer-causing gene ErbB-2 (also known as HER2) are extremely difficult to treat. In one recent study, the seven-year survival rate for women with this subgroup of breast cancers was only about 13 percent.

Clinicians have had some recent success in treating breast cancers with a mutated ErbB-2 gene, which are also referred to as being HER2-positive. The targeted therapy Herceptin blocks the mutation, improving the outlook for such patients, though it doesn't work in all cases. Sicinski said that a CDK4 inhibitor might be used in combination with Herceptin to provide further benefit in these patients.

If a drug to block CDK4 proved feasible, Sicinski said, it may be possible to test women's breast tumors for the presence of the overactive kinase, and then treat those
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
17-Jan-2006


Page: 1 2 3

Related biology news :

1. Unlocking proteins from their cellular shell
2. A new brake on cellular energy production discovered
3. MNI researchers find a new role for mitochondria in cellular copper regulation
4. Unicellular microRNA discovery
5. Stem cell identity in culture may strongly depend on the cellular microenvironment
6. UNC scientists discover cellular SOS signal in response to UV skin damage
7. Keeping the body in sync -- the stability of cellular clocks
8. Microfluidic chip helps solve cellular mating puzzle
9. Cold climate produced by algae contributed to onset of multicellular life
10. Turning a cellular sentinel into a cancer killer
11. Prenatal cocaines lasting cellular effects

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New cellular flaw found some virulent breast cancers

(Date:7/27/2014)... Using data from over 18,000 patients, scientists have ... involved in Parkinson,s disease, including six that had ... Nature Genetics , was partially funded by ... by scientists working in NIH laboratories. , "Unraveling ... understanding the multiple mechanisms involved in this complex ...
(Date:7/25/2014)... summer and some of the smoke from those fires is ... by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua ... descended over the Great Lakes region of the United States. ... July 23, 2014 (first image feature highlighted below) clearly shows ... In the image, it is over Manitoba and ...
(Date:7/25/2014)... associate professor of biomedical engineering at the University ... tissue engineering and artificial organ development., "Introduction to ... guide to entering into the field of artificial ... of biomedical engineering at UH, served as a ... while there are other published books on the ...
Breaking Biology News(10 mins):NIH scientists find 6 new genetic risk factors for Parkinson's 2University of Houston researcher publishes textbook on tissue engineering 2
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, ... for global corporations operating in highly regulated industries, ... first annual Global User Group Conference, Xybion International ... Philadelphia, Pennsylvania at the Sheraton ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s conference ...
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  Now available is a stem cell therapy that ... , located in Guadalajara, Mexico , ... new health option: stem cell therapies for sports ... suffer from joint and muscle injuries due to professional ... rotator cuff, tennis elbow, and knee injuries. Throughout life ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
Cached News: